Journal article Published 2021
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
BMC Cancer 21(1), 73 (2021)
- 2021 Year
- 33451293 PMID
Cite this publication
MINARIK, J., T. PIKA, J. RADOCHA, A. JUNGOVA, J. STRAUB, T. JELINEK, L. POUR, P. PAVLICEK, M. MISTRÍK, L. BROZOVA, P. KRHOVSKA, K. MACHALKOVA, P. JINDRA, I. SPICKA, H. PLONKOVA, M. STORK, J. BACOVSKY, L. CAPKOVA, M. SYKORA, P. KESSLER, L. STEJSKAL, A. HEINDORFER, J. ULLRYCHOVA, T. SKACEL, V. MAISNAR, R. HAJEK: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021, 21(1), 73, ISSN: 1471-2407, PMID: 33451293.
Details
- ISSN
- 1471-2407
